Institute of Biophysic Carlos Chagas Filho, Health Science Centre, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro-Rj, Brazil.
J Ren Nutr. 2012 May;22(3):350-6. doi: 10.1053/j.jrn.2011.05.002. Epub 2011 Jul 13.
Iron supplementation is a common recommendation to chronic kidney disease patients undergoing hemodialysis (HD). However, iron excess is closely associated with lipid peroxidation and, it is well known that electronegative low-density lipoproteins (LDL[-]) are present at higher plasma concentrations in diseases with high cardiovascular risk such as chronic kidney disease. Thus, the aim of this study was to investigate whether ferritin levels are associated with LDL(-) levels in HD patients.
This was a cross-sectional study.
This study was conducted from a private clinic in Rio de Janeiro, Brazil.
The study included 27 HD patients and 15 healthy subjects.
Twenty-seven HD patients (14 men, 58.6 ± 10 years, 62.2 ± 51.4 months on dialysis, and body mass index: 24.4 ± 4.2 kg/m(2)) were studied and compared with 15 healthy individuals (6 men, 53.8 ± 15.4 years, body mass index: 24.5 ± 4.3 kg/m(2)). Serum LDL(-) levels were measured using the enzyme-linked immunosorbent assay method; ferritin levels by commercially available kits, and tumor necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1, and plasminogen activator inhibitor-1 were determined with a multiplex assay kit manufactured by R&D Systems.
The HD patients presented higher LDL(-) and tumor necrosis factor-α levels (0.15 ± 0.13 U/L and 5.9 ± 2.3 pg/mL, respectively) than healthy subjects (0.07 ± 0.05 U/L and 2.3 ± 1.3 pg/mL, respectively) (P = .0001). The mean ferritin level in HD patients was 1,117.5 ± 610.4 ng/mL, and 90% of patients showed ferritin levels exceeding 500 ng/mL. We found a positive correlation between LDL(-) and ferritin in the patients (r = 0.48; P = .01), and ferritin was a significant contributor to LDL(-) concentrations independent of inflammation.
Excess body iron stores for HD patients was associated with signs of increased oxidative stress, as reflected by increased LDL(-) levels in HD patients.
铁补充剂是接受血液透析(HD)的慢性肾脏病患者的常见推荐。然而,铁过量与脂质过氧化密切相关,众所周知,带负电荷的低密度脂蛋白(LDL[-])在心血管风险较高的疾病中存在较高的血浆浓度,如慢性肾脏病。因此,本研究的目的是探讨铁蛋白水平与 HD 患者的 LDL[-]水平是否相关。
这是一项横断面研究。
本研究在巴西里约热内卢的一家私人诊所进行。
该研究纳入了 27 名 HD 患者和 15 名健康受试者。
研究纳入了 27 名 HD 患者(14 名男性,58.6 ± 10 岁,透析 62.2 ± 51.4 个月,体重指数:24.4 ± 4.2 kg/m²),并与 15 名健康个体(6 名男性,53.8 ± 15.4 岁,体重指数:24.5 ± 4.3 kg/m²)进行了比较。使用酶联免疫吸附测定法测量血清 LDL[-]水平;通过商业试剂盒测量铁蛋白水平;并通过 R&D Systems 制造的多重检测试剂盒测定肿瘤坏死因子-α、白细胞介素-6、单核细胞趋化蛋白-1 和纤溶酶原激活物抑制剂-1。
HD 患者的 LDL[-]和肿瘤坏死因子-α水平高于健康受试者(0.15 ± 0.13 U/L 和 5.9 ± 2.3 pg/mL 分别;0.07 ± 0.05 U/L 和 2.3 ± 1.3 pg/mL 分别)(P =.0001)。HD 患者的平均铁蛋白水平为 1117.5 ± 610.4 ng/mL,90%的患者铁蛋白水平超过 500 ng/mL。我们发现患者的 LDL[-]与铁蛋白之间存在正相关(r = 0.48;P =.01),并且铁蛋白是 LDL[-]浓度的一个重要贡献者,独立于炎症。
HD 患者体内铁储存过多与氧化应激标志物增加有关,表现为 HD 患者的 LDL[-]水平升高。